Related Experiment Video
Updated: Nov 20, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide
Sympascho Young1, Wei Liu1, Katherine Zukotynski2
1Department of Radiation Oncology, London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada.
Introduction:
PSMA-targeted PET/CT is a 'Next Generation Imaging' technique with superior sensitivity and specificity for detecting recurrent prostate cancer compared with conventional imaging, allowing more accurate staging and re-staging.
Areas Covered:
This article reviews the role of PSMA-targeted PET/CT in clinical management of men with recurrent prostate cancer.
Expert Opinion:
Through enhanced spatial characterization of recurrent prostate cancer, PSMA-targeted PET/CT has shown significant impact on management decisions. In particular, by identifying men with recurrence confined to the prostate or pelvic nodes, PSMA-targeted PET/CT enables selective deployment of localized salvage therapies for management of biochemical failure after primary treatment with prostatectomy or radiotherapy. In oligometastatic disease, PSMA-targeted PET/CT may improve patient selection and treatment accuracy for metastasis-directed therapy and early phase II studies show encouraging results in delaying the need for systemic therapy. Further, quantitative PSMA-targeted PET/CT for monitoring response and therapeutic PSMA-targeted radiopharmaceuticals are emerging as encouraging treatment options in the setting of castrate-resistant disease.
